October 20th, 2026Tezepelumab sustains EoE remission through 52 weeks Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.Read more
October 19th, 2026Mirikizumab meets 1-year remission end point in pediatric UCIn phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.Read more
November 13th, 2026Contemporary Pediatrics week in review: November 9-13, 2026Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.Read more
November 13th, 2026Stock epinephrine improves school allergy safety, nurse survey findsSchools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.Read more
November 13th, 2026Dupilumab for early EoE linked to lower asthma risk in young childrenIn a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).Read more
November 12th, 2026Language barriers linked to lower early peanut introduction ratesNon-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.Read more
November 12th, 2026Clinicians order food allergy panels despite false-positive riskIn an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.Read more
November 12th, 2026Risankizumab shows 52-week efficacy in pediatric psoriasis trialFull OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.Read more